Updates are available Correction dated 2022-04-12
Click to view Correction: https://doi.org/10.1038/s41467-022-29844-x
-
Authors
Toral, Marcus A.
Charlesworth, Carsten T.
Ng, Benjamin https://orcid.org/0000-0003-4296-2948
Chemudupati, Teja
Homma, Shota
Nakauchi, Hiromitsu https://orcid.org/0000-0002-9841-6973
Bassuk, Alexander G. https://orcid.org/0000-0002-4067-2157
Porteus, Matthew H. https://orcid.org/0000-0002-3850-4648
Mahajan, Vinit B. https://orcid.org/0000-0003-1886-1741
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01EY031952, R01EY030151, R01EY025225, R01EY024698, P30EY026877)
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute
Research to Prevent Blindness
- License Information
-
More Information
Article History
Received: 15 March 2021
Accepted: 4 February 2022
First Online: 25 February 2022
Change Date: 12 April 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-022-29844-x
Competing interests
: V.B.M is a co-founder and holds equity Eurdora and serves as an advisor for which he receives compensation from Replay. M.H.P. is a co-founder and Board member of Graphite Bio and holds equity in CRISPR Tx. He has equity and serves on the Scientific Advisory Board of Allogene Tx and Ziopharma Tx. He serves as an advisor for which he receives compensation from Versant Ventures. These companies had no input into this work. H.N. serves on the Scientific Advisory Board and holds equity in Century Therapeutics, QihanBiotech, and Megakaryon Corp, but these companies had no input into this work. The remaining authors declare no competing interests.
